ROQUIN/RC3H1 alterations are not found in angioimmunoblastic T-cell lymphoma. by Auguste, Tiphanie et al.
ROQUIN/RC3H1 alterations are not found in
angioimmunoblastic T-cell lymphoma.
Tiphanie Auguste, Marion Travert, Karin Tarte, Patricia Ame´-Thomas,
Catherine Artchounin, Nadine Martin-Garcia, Aure´lien De Reynies, Laurence
De Leval, Philippe Gaulard, Marie-He´le`ne Delfau-Larue
To cite this version:
Tiphanie Auguste, Marion Travert, Karin Tarte, Patricia Ame´-Thomas, Catherine Artchounin,
et al.. ROQUIN/RC3H1 alterations are not found in angioimmunoblastic T-cell lym-
phoma.. PLoS ONE, Public Library of Science, 2013, 8 (6), pp.e64536. <10.1371/jour-
nal.pone.0064536>. <inserm-00868981>
HAL Id: inserm-00868981
http://www.hal.inserm.fr/inserm-00868981
Submitted on 2 Oct 2013
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

ROQUIN/RC3H1 Alterations Are Not Found in
Angioimmunoblastic T-Cell Lymphoma
Tiphanie Auguste1,2, Marion Travert1, Karin Tarte3, Patricia Ame´-Thomas3, Catherine Artchounin1,6,
Nadine Martin-Garcia1,6, Aure´lien de Reynies4, Laurence de Leval5, Philippe Gaulard1,2,6, Marie-
He´le`ne Delfau-Larue1,2,7*
1 INSERM U955, Immunologie et Oncogene`se des Tumeurs Lymphoı¨des, Cre´teil, France, 2 Faculte´ de Me´decine, Universite´ Paris-Est, Cre´teil, France, 3 INSERM U917,
Microenvironnement et Cancer, Rennes, France, 4 Programme Cartes d’Identite´ des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France, 5 Service de Pathologie
Clinique, Institut Universitaire de Pathologie, Lausanne, Switzerland, 6De´partement de Pathologie, Groupe Hospitalier Henri Mondor–Albert Chenevier, Cre´teil, France,
7 Laboratoire d’Immunologie Biologique, Assistance Publique–Hoˆpitaux de Paris (AP-HP), Groupe Henri-Mondor Albert-Chenevier, Cre´teil, France
Abstract
Angioimmunoblastic T-cell Lymphoma (AITL) is one of the most frequent T-cell lymphoma entities. Follicular helper T
lymphocytes (TFH) are recognized as the normal cellular counterpart of the neoplastic component. Despite a clonal T-cell
feature and few described recurrent cytogenetic abnormalities, a driving oncogenic event has not been identified so far. It
has been recently reported that in mice, heterozygous inactivation of Roquin/Rc3h1, a RING type E3 ubiquitine ligase,
recapitulates many of the clinical, histological, and cellular features associated with human AITL. In this study we explored
whether ROQUIN alterations could be an initial event in the human AITL oncogenic process. Using microarray and RT-PCR
analyses, we investigated the levels of ROQUIN transcripts in TFH tumor cells purified from AITL (n = 8) and reactive tonsils
(n = 12) and found similar levels of ROQUIN expression in both. Moreover, we also demonstrated that ROQUIN protein was
expressed by AITL TFH (PD1+) cells. We then analysed ROQUIN coding sequence in 12 tumor cell-rich AITL samples and
found no mutation in any of the samples. Finally, we analysed the expression of MiR101, a putative partner of ROQUIN
involved in the modulation of ICOS expression and found similar levels of expression in tumor and reactive TFH. Altogether,
this study shows that neither alteration of ROQUIN gene nor deregulation of miR101 expression is likely to be a frequent
recurrent event in AITL.
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Introduction
Angioimmunoblastic T-cell Lymphoma (AITL) is a distinct T-
cell lymphoma entity [1] originally described as a dysimmune
condition [2]. It usually manifests with generalized lymphadenop-
athy, hepatomegaly, splenomegaly, fever, sweats, and skin rash
and is frequently associated with clinical and biological auto-
immune manifestations [3]. A clonal T-Cell Receptor gene
rearrangement is detected in around 80% of the cases [4,5], and
few recurrent cytogenetic abnormalities have been reported
(reviewed in [6]). Recently, we have reported mutations in
isocitrate dehydrogenases 2 (IDH2) [7] and Ten-Eleven Translo-
cation 2 (TET2) [8] genes in AITL, two genes involved in
epigenetic gene regulation, but to date, no driving oncogenic event
has been identified. We and others have shown that Follicular
Helper T (TFH) cells are the normal cellular counterpart of the
neoplastic component of AITL [9–12]. TFH cells constitute a
specialized subset of T cells which allows the selection of high-
affinity B lymphocytes within germinal centers and provide helper
function for antibody production [13]. Human TFH cells express
high levels of BCL6, PD1, ICOS, the chemokine CXCL13 and its
receptor (CXCR5) and secrete the cytokine IL-21 [14–18].
Recently, a mouse model has been proposed for AITL [19]. It
recapitulates many of the clinical and pathological features
associated with AITL, including lymphadenopathy, hypergamma-
globulinemia and accumulation/expansion of clonal TFH cells.
This phenotype is specifically linked to heterozygous Roquin/Rc3h1
point mutation (sanroque allele) in T cells [20]. Roquin, a RING-
type E3 ubiquitin ligase family member, has been previously
identified as a regulator of autoimmune responses in mice [20].
We thus hypothesized that in human, ROQUIN/RC3H1
alterations could occur as an initial event of the AITL oncogenic
process, leading to TFH accumulation or proliferation prone to
subsequent transforming events.
Material and Methods
The present study was approved by the institutional review
board ‘‘Comite´ de Protection des Personnes, Cre´teil, France»
(CPP 09–008). Written consent was obtained from patients with
lymphoma. Reactive human tonsils were collected from children
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undergoing routine tonsillectomy. Oral information was given to
parents. A consent form attesting the oral consent was signed by
the surgeon and given to the research team with tonsils.
Cell samples and AITL tissues
Normal cell subsets were isolated from reactive human tonsils.
Briefly, mononuclear cells were isolated by mechanical disruption
followed by Ficoll-hypaque density gradient centrifugation. TFH
cells were purified after depletion of CD19, CD8, CD14 and
CD16-positive cells with magnetic beads (Milteny Biotec, Paris,
France), by cell sorting of CD4-FITC, CXCR5-PE and ICOS-
PC7 triple-positive cells on Mo-Flo legacy (Beckman Coulter,
Villepinte, France). Tonsil CD4+, CD8+ T-cells and B-cells were
purified by positive selection with antibodies directed against CD4,
CD8, and CD19 respectively (Milteny Biotec, Paris, France).
Neoplastic TFH cells were isolated from cryopreserved mononu-
clear cell suspensions of AITL lymph node biopsies, through a
one-step CD4-FITC, CXCR5-PE and ICOS-PC7 cell sorting.
Twelve AITL tumor frozen tissue samples were selected on the
basis of high tumor cell content. After complete immunostaining
for TFH markers including PD1, ICOS and CXCL13, a semi-
quantitative evaluation of tumor cells was performed as previously
described [21] and cases with more than 50% tumor cells were
selected for ROQUIN sequence analyses (Figure 1).
Immunohistochemistry
For in situ evaluation of ROQUIN expression, deparaffinised
tissue sections of 8 AITL samples were stained with a polyclonal
antibody (Novius biologicals NBP1-89590, Cambridge, United
Kingdom) using a Vectastain immunoperoxidase method (Vector
Labs, Peterborough, UK) and revealed with Diaminobenzidine
(DAB). Specificity of the antibody was validated using NIH3T3
transfected with human full length ROQUIN cDNA (data not
shown). The distribution and phenotypic characteristics of
ROQUIN-positive cells in vivo was explored by double immuno-
stainings for ROQUIN and either PAX5 (as a B-cell marker) and
PD1 (as TFH marker). Briefly, cases were first stained for
ROQUIN using an immunoperoxidase method (Vectastain), then
for PAX5 ((DakoCytomation, Glostrup, Denmark) or PD1
Figure 1. Illustrative case of AITL rich in tumor cells. Diffuse
proliferation of large neoplastic cells surrounded by inflammatory cells
(plasma cells, eosinophils) and vascular hyperplasia (hematoxylin-eosin,
original magnification620) (A). Numerous neoplastic cells highlighted
by positivity for TFH markers CXCL13 (B), ICOS (C) and PD1(D)
(immunoperoxidase, original magnification620).
doi:10.1371/journal.pone.0064536.g001
Figure 2. ROQUIN expression in human reactive and tumoral lymphoid samples. Levels of ROQUIN transcripts determined by gene
expression profiling of 17 AITL tumor tissue samples and 2 AITL cell suspensions enriched in tumor cells ($50%) samples as previously reported [10].
(probe-set 228996_at): ROQUIN transcripts level is slightly higher in enriched tumor cell sample (P = 0,0067 unpaired t-test) (A). ROQUIN mRNA levels
determined by quantitative RT-PCR in reactive tonsils; total extract (n = 1), CD4+ (n = 2), CD8+ (n = 2), or CD19+ (n = 2) lymphocytes. Results were
normalized by HPRT and compared to reactive purified TFH cells as calibrator: reactive CD4- CD8- and CD19-positive subsets display heterogeneous
levels of ROQUIN mRNA (B). ROQUIN mRNA levels [(228996_at) probeset] in purified reactive (n = 12) and neoplastic TFH cells (n = 8). TFH cells were
purified from 12 reactive tonsils and 8 AITL lymph nodes, RNA was extracted and whole genome expression was analysed on HG-U133 plus 2.0
Affymetrix GeneChip arrays. Similar levels of ROQUIN transcript are observed (C).
doi:10.1371/journal.pone.0064536.g002
Figure 3. Immunohistochemical detection of ROQUIN in AITL.
Among the many cells showing a cytoplasmic granular staining for
ROQUIN (brown), a few are PAX5-positive large cells (B-immunoblasts)
(pink arrow) whereas most of them are small to medium-sized PAX5-
negative lymphoid cells forming small aggregates, corresponding to
neoplastic cells of AITL (black arrows) (A). In addition, these aggregates
of medium-sized ROQUIN- positive cells (brown, granular staining) co
expressed the TFH-associated marker PD1 (red, membrane staining) (B).
Double immunohistochemistry, original magnification6250.
doi:10.1371/journal.pone.0064536.g003
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(ABCAM, Cambridge, UK) using a Vectastain phosphatase
alkaline method (Vector Labs) and revealed with Naphtol fast
red. Images were captured with a Zeiss Axioskop2 microscope
(Zeiss). Photographs were taken with an Olympus DP70 camera.
Images were acquired with Olympus DP Controller and images
were processed with Adobe Photoshop Version 7.0 (Adobe
Systems).
Microarray and RT-PCR analysis
Total RNAs extracted using TRIZOL reagent (Invitrogen,
Carlsbad, CA) were used either for microarray procedures on HG-
U133 plus 2.0 Affymetrix GeneChip array) as previously described
[12] or for microRNA gene expression profiling on Agilent
Human v3 miRNA microarray (G4471A, Agilent, Santa Clara
CA). Analyses of gene expression profiles focused on probesets
matching to ROQUIN (228996_at), ICOS (210439_at), and on
miR101 (has-miR-101). The levels of ROQUIN and ICOS
transcripts in reactive and neoplastic TFH were determined by
TaqMan quantitative reverse-transcriptase PCR (qRT-PCR;
Applied Biosystems) on Light Cycler 480, after normalization to
HPRT mRNA, and compared to purified reactive TFH, according
to the 2DDCT method.
Sequence analyses
ROQUIN cDNA was amplified by PCR in 3 fragments
encompassing the coding sequence. Direct sequencing of PCR
products was performed for the first two 59 fragments. A cloning
phase was necessary for exons 16 to 19 sequencing due to
alternative splicing. Sequences were obtained on a 3130X1 genetic
analyzer (Applied biosystems) and compared with the ROQUIN
reference sequence (GenBank accession number NM_172071)
using seqscape software. PCR and sequencing primers are
available upon request. It has been established that this sequencing
method allows the detection of a mutated allele when it represents
10% or more of the total amplified alleles [22].
Results and Discussion
The levels of ROQUIN transcripts are similar in neoplastic
and reactive TFH cells
The analyses of ROQUIN probesets in our previously published
transcriptomic dataset [12] disclosed the presence of ROQUIN
transcripts in 17/17 AITL tissue samples with a slightly higher
level in the two AITL cell-sorted samples enriched in tumor cells
(n = 2) (Figure 2A). However, as reactive T (CD4, CD8) and B
(CD19) cell subsets also contain ROQUIN mRNA (Figure 2B) and
may thus compound the precise analysis of ROQUIN level of
expression in tumor TFH, we thus performed additional tran-
scriptomic analyses of CD4+/CXCR5+/ICOS+ sorted TFH cells
obtained from reactive tonsils (n = 12) and AITL (n = 8) on
Affymetrix microarray. Similar levels of ROQUIN transcripts were
observed in TFH purified either from reactive tonsils or from AITL
lymph nodes (Figure 2C), thus excluding the hypothesis of a
ROQUIN extinction by promoter alteration or gene expression
dysregulation in AITL.
ROQUIN protein is expressed by AITL tumor cells
In situ evaluation of the pattern of ROQUIN expression was
performed by immunohistochemistry. In all eight AITL cases
investigated, numerous cells showing a granular cytoplasmic
staining were observed. These comprised scattered large cells
resembling B-blasts, smaller lymphocytes and many small to
medium-sized atypical cells suggestive of the neoplastic cell
component, as well as endothelial cells (Figure 3A). Double
immunostainings performed in 4 cases demonstrated that most
ROQUIN-positive cells were PAX5-negative and that many of
them expressed PD1, therefore sharing the characteristic mor-
phological and phenotypic features of neoplastic TFH cells
(Figure 3B). Furthermore, the observed granular cytoplasmic
staining is compatible with Roquin localization in P bodies or
stress granules as reported in the mouse [23,24].
ROQUIN coding sequence is not mutated in human AITL
We next investigated the presence of missense mutations in
ROQUIN coding sequence. The 3402 bp ROQUIN coding
sequence was obtained from 12 AITL samples with a high tumor
load as well as normal CD4+ T cells sorted from 2 reactive tonsils.
In contrast to Sanroque mice that develop a TFH cell
lymphoproliferative disorder with several symptoms of AITL
including auto-immune manifestations and organomegaly as a
result of Roquin mutations [19], no mutation was found in any of
the AITL patients.
ICOS and miR101 expression are similarly expressed in
reactive and AITL TFH
Physiologically, in mice, Roquin limits ICOS expression by
promoting the degradation of ICOS mRNA in a dose-dependent
manner [24,25]. In sanroque mice, mutated Roquin is unable to
promote ICOS mRNA degradation, resulting in the overexpression
of the protein. Here, we show that the level of ICOS mRNA
expression is maintained even in the presence of ROQUIN
transcripts both in human reactive and tumor TFH cells
Figure 4. Expression of ICOS and miR101 expression in human reactive and neoplastic TFH cells. Analyses of ICOS expression
(210439_at). The level of ICOS mRNA expression is maintained even in the presence of ROQUIN transcripts both in human reactive and tumor TFH cells
(A) Level of miR101 (has-miR-101) is low and similar in both tumor and reactive TFH cells (p = 0,8 unpaired t-test, NS) (B).
doi:10.1371/journal.pone.0064536.g004
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(Figure 4A). This is in accordance with the common ICOS
expression by neoplastic T-cells in AITL [26,27]. It has been
suggested that Roquin repressive effect on ICOS transcripts
requires miR101 expression [25]. We therefore looked for miR101
expression in our TFH cells. Level of miR101 was low and similar
in both neoplastic and reactive TFH cells (Figure 4B), in
accordance with recent finding in mouse showing that BCL6
could repress inhibitors of specific TFH expressing gene including
miR101 [28].
Conclusion
Altogether, by comparing reactive and AITL TFH cells, we have
shown here that neither alteration of ROQUIN gene nor
deregulation of miR101 expression is likely to be a frequent
recurrent abnormality in AITL. Expanding knowledge on the
pathways deregulated by Roquin mutation in Sanroque mice might
uncover other molecules of potential relevance to AITL patho-
physiology.
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